Cited by 1,258Polyomavirus and related diseasesCancer Immunotherapy and BiomarkersNonmelanoma Skin Cancer Studies

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Open access

Nghiem, Paul T., Bhatia, Shailender, Lipson, Evan J., Kudchadkar, Ragini R., Miller, Natalie J., Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K., Daud, Adil, Fling, Steven P., Friedlander, Philip A., Kluger, Harriet M., Kohrt, Holbrook E., Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M., Reddy, Sunil A., Shantha, Erica M., Sharfman, William H., Sharon, Elad, Shemanski, Lynn R., Shinohara, Michi M., Sunshine, Joel C., Taube, Janis M., Thompson, John A., Townson, Steven M., Yearley, Jennifer H., Topalian, Suzanne L., Cheever, Martin A.·2016·New England Journal of Medicine

DOI 10.1056/nejmoa1603702PMC PMC4927341

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell carcinoma often responds to chemotherapy, but responses are transient. Blocking the programmed death 1 (PD-1) immune inhibitory pathway is of interest, because these tumors often express PD-L1, and MCPyV-specific T cells express PD-1. METHODS: In this multicenter, phase 2, noncontrolled study, we assigned adults with advanced Merkel-cell carcinoma who had received no previous systemic therapy to receive pembrolizumab (anti-PD-1) at a dose of 2 mg per kilogram of body weight every 3 weeks. The primary end point was the objective response rate according to Response Evaluation Criteria in Solid Tumors, version 1.1. Efficacy was correlated with tumor viral status, as assessed by serologic and immunohistochemical testing. RESULTS: A total of 26 patients received at least one dose of pembrolizumab. The objective response rate among the 25 patients with at least one evaluation during treatment was 56% (95% confidence interval [CI], 35 to 76); 4 patients had a complete response, and 10 had a partial response. With a median follow-up of 33 weeks (range, 7 to 53), relapses occurred in 2 of the 14 patients who had had a response (14%). The response duration ranged from at least 2.2 months to at least 9.7 months. The rate of progression-free survival at 6 months was 67% (95% CI, 49 to 86). A total of 17 of the 26 patients (65%) had virus-positive tumors. The response rate was 62% among patients with MCPyV-positive tumors (10 of 16 patients) and 44% among those with virus-negative tumors (4 of 9 patients). Drug-related grade 3 or 4 adverse events occurred in 15% of the patients. CONCLUSIONS: In this study, first-line therapy with pembrolizumab in patients with advanced Merkel-cell carcinoma was associated with an objective response rate of 56%. Responses were observed in patients with virus-positive tumors and those with virus-negative tumors. (Funded by the National Cancer Institute and Merck; ClinicalTrials.gov number, NCT02267603.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1603702

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citation
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 3

10.2307/2281868 · DOI · Paper page
Berger RL, 1996, Am Stat, 50, 314
Behr DS, 2014, Int J Clin Exp Pathol, 7, 7610

Sorted by citations

Items 701–800 of 1,000

PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma
Yang, Z., Zhang, L., Liu, J., Yang, L., Xue, H. Y., Bai, S., & Wang, K. (2021) · Translational Cancer Research · doi:10.21037/tcr-20-3415 · Cited by 11
Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome
Zou, R., Wang, Y., Ye, F., Zhang, X., Wang, M., & Cui, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02637-2 · Cited by 11
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
Robinson, M., Livesey, D., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156870 · Cited by 11
Insights into anti-tumor immunity via the polyomavirus shared across human Merkel cell carcinomas
Jani, S., Church, C. D., & Nghiem, P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172913 · Cited by 11
Self-citation
Enhancing immunogenic responses through CDK4/6 and HIF2α inhibition in Merkel cell carcinoma
Lee, J. H., Lee, J. D., Paulson, K. G., Voillet, V., Berndt, A., Church, C. D., Lachance, K., Park, S. Y., Yamamoto, N., Cromwell, E. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23521 · Cited by 11
Self-citation
Treating tumors with immune checkpoint inhibitors: Rationale and limitations
Seidel, J. A., Otsuka, A., & Kabashima, K. (2017) · Trends in Immunotherapy · doi:10.24294/ti.v1.i1.20 · Cited by 11
Poly ADP‐ribose polymerase‐1 as a potential therapeutic target in Merkel cell carcinoma
Ferrarotto, R., Cardnell, R. J., Su, S. Y., Diao, L., Eterovic, A. K., Prieto, V. G., Morrisson, W. H., Wang, J., Kies, M. S., Glisson, B. S., et al. (2018) · Head & Neck · doi:10.1002/hed.25146 · Cited by 11
Selective Inhibition of Aurora Kinase A by AK-01/LY3295668 Attenuates MCC Tumor Growth by Inducing MCC Cell Cycle Arrest and Apoptosis
Das, B. K., Kannan, A., Nguyen, Q., Gogoi, J., Zhao, H., & Gao, L. (2021) · Cancers · doi:10.3390/cancers13153708 · Cited by 11
Inhibition of T-antigen expression promoting glycogen synthase kinase 3 impairs merkel cell carcinoma cell growth
Houben, R., Hesbacher, S., Sarma, B., Schulte, C., Sarosi, E., Popp, S., Adam, C., Kervarrec, T., & Schrama, D. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.031 · Cited by 11
Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
Chen, R., Peng, L., Qiu, Z., Wang, Y., Wei, F., Zhou, M., & Zhu, F. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.727445 · Cited by 11
Neutron Radiation Therapy for Treatment of Refractory Merkel Cell Carcinoma
Macomber, M. W., Tarabadkar, E. S., Mayr, N. A., Laramore, G. E., Bhatia, S., Tseng, Y. D., Liao, J. J., Arbuckle, T., Nghiem, P., & Parvathaneni, U. (2017) · International Journal of Particle Therapy · doi:10.14338/ijpt-17-00003.1 · Cited by 11
Self-citation
Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal
Morris, V. K., & Eng, C. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7040 · Cited by 11
Intraoperative Flurbiprofen Treatment Alters Immune Checkpoint Expression in Patients Undergoing Elective Thoracoscopic Resection of Lung Cancer
Hu, J., Chai, X., Wang, D., Shu, S., Magnussen, C. G., Xie, L.-X., & Hu, S. (2019) · Medical Principles and Practice · doi:10.1159/000503166 · Cited by 11
Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell Killing In Vitro and In Vivo
Luly, K. M., Green, J. J., Sunshine, J. C., & Tzeng, S. Y. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00885 · Cited by 10
Self-citation
Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances
Lessans, S., O’Connell, K. A., & Choe, J. H. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01570-1 · Cited by 11
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Mortier, L., Villabona, L. E. E., Lawrence, B. J., Arance, A. M., Butler, M. O., Beylot-Barry, M., Saïag, P., Samimi, M., Ascierto, P. A., Spada, F., et al. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00885-w · Cited by 10
Common biological processes and mutual crosstalk mechanisms between cardiovascular disease and cancer
Gao, H., Chen, Z., Yao, Y., He, Y., & Hu, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1453090 · Cited by 11
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial
Kendra, K. L., Bellasea, S. L., Eroglu, Z., Hu‐Lieskovan, S., Campbell, K. M., Carson, W. E., Wada, D. A., Plaza, J. A., Sosman, J. A., In, G. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03875-5 · Cited by 10
Self-citation
Large‐cell variant of Merkel cell carcinoma with clear‐cell change
Khanna, U., & North, J. P. (2019) · Journal of Cutaneous Pathology · doi:10.1111/cup.13583 · Cited by 10
Deciphering the dual role and prognostic potential of PINK1 across cancer types
Radin, D., Dai, K., & Leonardi, D. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.295314 · Cited by 10
Drug Development in Neuroendocrine Tumors: What Is on the Horizon?
García‐Álvarez, A., Cubero, J. H., & Capdevila, J. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00834-3 · Cited by 10
Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel
Bhanegaonkar, A. J., Liu, F. X., Boyd, M., Fulcher, N. M., Kim, R., Krulewicz, S., Smith, J., & Cowey, C. L. (2021) · The Oncologist · doi:10.1002/onco.13845 · Cited by 10
Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies
Goodman, R. S., & Johnson, D. B. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01018-3 · Cited by 10
Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review
Akaike, T., Cahill, K., Akaike, G., Huynh, E. T., Hippe, D. S., Shinohara, M. M., Liao, J. J., Apisarnthanarax, S., Parvathaneni, U., Hall, E. T., et al. (2022) · Cancers · doi:10.3390/cancers14235914 · Cited by 10
Self-citation
Avelumab for the treatment of metastatic Merkel cell carcinoma
Cordes, L. M., & Gulley, J. L. (2017) · Drugs of today · doi:10.1358/dot.2017.53.7.2654888 · Cited by 10
Novel Technology to Assess Programmed Death-Ligand 1 Expression by Multiplex Immunofluorescence and Image Analysis
Parra, E. R. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000610 · Cited by 10
Successful immunotherapy and irradiation in a HIV-positive patient with metastatic Merkel cell carcinoma
Linge, A., Rauschenberg, R., Blum, S. F. U., Spornraft‐Ragaller, P., Meier, F. E., & Troost, E. G. C. (2018) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2018.12.004 · Cited by 10
A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients
Rastrelli, M., Fiore, P. D., Buja, A., Vecchiato, A., Rossi, C. R., Chiarion‐Sileni, V., Tropea, S., Russano, F., Zorzi, M., Spina, R., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00529 · Cited by 10
Real-World Outcomes Among US Merkel Cell Carcinoma Patients Initiating Immune Checkpoint Inhibitors or Chemotherapy
Chandra, S., Zheng, Y., Pandya, S., Yu, T., Kearney, M., Wang, L., Kim, R., & Phatak, H. M. (2020) · Future Oncology · doi:10.2217/fon-2020-0453 · Cited by 10
Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis
Buñuales, M., Ballesteros-Briones, M. C., González-Aparicio, M., Hervás‐Stubbs, S., Martišová, E., Mancheño, U., Ricobaraza, A., Lumbreras, S., Smerdou, C., & Hernández-Alcoceba, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084176 · Cited by 10
Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours
Wang, S., Huang, H., Wu, D., Fang, H., Ying, J., Bai, Y., Yu, Y., Fang, Y., Jiang, N., Sun, C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044543 · Cited by 10
Antitumor and Anti–Hepatitis C Viral Response After Administration of the Anti–Programmed Death 1 Antibody Pembrolizumab
Jang, S., & Venna, S. S. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2016.019224 · Cited by 10
Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications
Walsh, N. M. G., Castonguay, M., Carter, M. D., Pasternak, S., Ly, T. Y., Doucette, S. P., Hanly, J. G., Saggini, A., & Cerroni, L. (2019) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001390 · Cited by 10
PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology
Oh, K. S., & Mahalingam, M. (2019) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001287 · Cited by 10
Oncologic outcomes of patients with Merkel Cell Carcinoma (MCC): A multi-institutional cohort study
Bleicher, J. M., Asare, E. A., Flores, S., Bowles, T. L., Bowen, G. M., & Hyngstrom, J. R. (2020) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2020.08.013 · Cited by 10
Myeloid-derived suppressor cells in gastroenteropancreatic neuroendocrine neoplasms
Liu, M., Zhang, Y., Chen, L., Lin, Y., He, Q., Zeng, Y., Chen, M., & Chen, J. (2020) · Endocrine · doi:10.1007/s12020-020-02467-2 · Cited by 12
Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
Ricco, G., Andrini, E., SIEPE, G., Mosconi, C., Ambrosini, V., Ricci, C., Casadei, R., Campana, D., & Lamberti, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910629 · Cited by 10
Extended T-Cell Epitope Landscape in Merkel Cell Polyomavirus Large T and Small T Oncoproteins Identified Uniquely in Patients with Cancer
Hansen, U. K., Lyngaa, R., Ibrani, D., Church, C. D., Verhaegen, M. E., Dlugosz, A. A., Becker, J. C., Straten, P. T., Nghiem, P., & Hadrup, S. R. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.06.027 · Cited by 9
Self-citation
Macrophages and fibroblasts underpin skin immune responses
Sugaya, M. (2021) · Exploration of Immunology · doi:10.37349/ei.2021.00015 · Cited by 9
Pembrolizumab Compared with Standard-of-Care Observation in Treating Patients with Completely Resected Stage I–III Merkel Cell Cancer (STAMP)
Teke, M. E., Rossi, A. J., Hernandez, J. M., & Gastman, B. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11498-0 · Cited by 9
Baseline ultrasound and FDG‐PET/CT imaging in Merkel cell carcinoma
Zijlker, L. P., Bakker, M., van der Hiel, B., Bruining, A., Klop, W. M. C., Zuur, C. L., Wouters, M. W. J. M., & van Akkooi, A. C. J. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27193 · Cited by 9
S2k‐Leitlinie – Merkelzellkarzinom – Update 2022
Becker, J. C., Beer, A. J., DeTemple, V. K., Eigentler, T., Flaig, M. J., Gambichler, T., Grabbe, S., Höller, U., Klumpp, B. D., Lang, S., et al. (2023) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14930_g · Cited by 9
Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice
Tang, X., Li, Y., Huang, H., Shi, R., Shen, L.-T., Qian, W., & Yang, Z. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04782-3 · Cited by 9
The prognostic value of TMB in early-stage non-small cell lung cancer: a systematic review and meta-analysis
Wankhede, D., Grover, S., & Hofman, P. M. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231195199 · Cited by 9
Peripheral blood PD-1+ T lymphocytes as biomarkers in liquid biopsies for solid tumors: Clinical significance and prognostic applications
Piao, M., Zhang, N., Li, J., Li, C., Xun, Z., Zhang, L., Wang, S., Sun, B., Li, S., Xu, Y., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114052 · Cited by 9
Recurrent Merkel cell carcinoma of the gluteal region: A case report
Türkkan, G., Agdoğan, Ö., Saynak, M., Uygun, A. C., & Üstün, F. (2018) · Dermatologic Therapy · doi:10.1111/dth.12749 · Cited by 9
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Zarifa, A., Salih, M., Lopez‐Mattei, J., Lee, H. J., Iliescu, C., Hassan, S. A., Palaskas, N. L., Durand, J., Mouhayar, E., Kim, J. D., et al. (2018) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_15_18 · Cited by 9
Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
Chanal, J., Kramkimel, N., Ratour, C., Aractingi, S., Guégan, S., & Avril, M. (2019) · Dermatology · doi:10.1159/000492467 · Cited by 9
Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
Adashek, J. J., Aguiar, P. N., Galanina, N., & Kurzrock, R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0618-9 · Cited by 9
Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma
Garcia, G. A., & Kossler, A. L. (2020) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000306 · Cited by 9
Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy
Marchand, A., Kervarrec, T., Bhatia, S., & Samimi, M. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1835477 · Cited by 9
Self-citation
Characterization of molecular pathways for targeting therapy in glioblastoma
Wagle, N. A., Nguyen, M., Carrillo, J., Truong, J., Dobrawa, L., & Kesari, S. (2020) · Chinese Clinical Oncology · doi:10.21037/cco-20-124 · Cited by 9
Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio, N., & Abdel-Rahman, O. M. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00817-4 · Cited by 9
Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies
Chong, P. Y., Iqbal, J., Yeong, J. P.-S., Aw, T. C., Chan, K. S., & Chui, P. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.658932 · Cited by 9
Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy
Li, X., Liang, W., Zhao, H., Jin, Z., Shi, G., Xie, W., Wang, H., & Wu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.749157 · Cited by 10
High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression
Bahr‐Hamm, K., Zimmer, S., Springer, E., Fottner, C., Becker, S., Ernst, B. P., Matthias, C., & Künzel, J. (2019) · ORL · doi:10.1159/000502325 · Cited by 9
Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma
Das, S., & Cardin, D. B. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00763-7 · Cited by 9
Miniature Fiber-Spectrophotometer for Real-Time Biomarkers Detection
Lazarjan, V. K., Gashti, A. B., Feshki, M., Garnier, A., & Gosselin, B. J. (2021) · IEEE Sensors Journal · doi:10.1109/jsen.2021.3072578 · Cited by 9
Merkel Cell Polyomavirus Antibody Titer Predicts Recurrence-Free Survival
Arroyave, A. J., Lewis, J. M., Landry, M., McLoughlin, J. M., & Enomoto, L. M. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11008-8 · Cited by 9
Challenges of New Approaches in Metastatic Merkel Cell Carcinoma
Monteiro, A., Gouveia, E. J., Garcez, D., Donato, S., Martins-Branco, D. A., Marques, J., Nunes, H., Passos, M. J., Clara, A. I., & Moreira, A. (2020) · Case Reports in Oncology · doi:10.1159/000507279 · Cited by 9
Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma
Lahman, M. C., Paulson, K. G., Nghiem, P., & Chapuis, A. G. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.12.037 · Cited by 9
Self-citation
Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy
Vandeven, N. A., & Nghiem, P. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.014498 · Cited by 9
Self-citation
Immune Checkpoint Inhibitors in Merkel Cell Carcinoma of the Skin: A 2025 Comprehensive Review
Tai, P., Alqaisi, O., Al‐Ghabeesh, S. H., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K. R., & Joseph, K. J. (2025) · Cancers · doi:10.3390/cancers17193272 · Cited by 8
Stenotrophomonas-maltophilia inhibits host cellular immunity by activating PD-1/PD-L1 signaling pathway to induce T-cell exhaustion
Wang, M., Yin, S., Qin, Q., Peng, Y., Hu, Z., Zhu, X., Liu, L., & Li, X. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.12.019 · Cited by 8
Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
Wang, Y., Li, M., Wang, G., & Wu, H. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1091383 · Cited by 8
Association of Merkel Cell Polyomavirus Status With p53, RB1, and PD-L1 Expression and Patient Prognosis in Merkel Cell Carcinomas: Clinical, Morphologic, and Immunohistochemical Evaluation of 17 Cases
Öğüt, B., Bayram, E. K., İnan, M. A., Kestel, S., & Erdem, Ö. (2023) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001127 · Cited by 8
Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis
Song, W., Zhang, N., Lv, T., Zhao, Y., Li, G., Tse, G., & Liu, T. (2024) · Cancer Innovation · doi:10.1002/cai2.109 · Cited by 8
Revolutionizing Skin Cancer Treatment: The Rise of PD-1/PDL-1 and CTLA-4 as Key Therapeutic Targets
Sharma, N., Mazumder, R., & Rai, P. (2024) · Current Drug Targets · doi:10.2174/0113894501320281240822052657 · Cited by 8
Programmed cell death protein-1 inhibitors for immunotherapy of advanced nonmelanoma skin cancer: showing early promise
Soura, E., Chasapi, V., & Stratigos, A. J. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14905 · Cited by 8
Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma
Bénigni, P., Guénolé, M., Bonsang, B., Marcorelles, P., Schick, U., & Uguen, A. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000792 · Cited by 8
Rapid onset type 1 diabetes associated with the programmed cell death‐1 inhibitor pembrolizumab
Boyle, V., Cundy, T., & Cutfield, R. G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14340 · Cited by 8
Merkel Cell Carcinoma of the Head and Neck Compared to Other Anatomical Sites in a Real-World Setting: Importance of Surgical Therapy for Facial Tumors
Heppt, M. V., Kirchberger, M. C., Schuler, G., Berking, C., & Heinzerling, L. (2019) · Facial Plastic Surgery · doi:10.1055/s-0039-3401805 · Cited by 8
Merkelzellkarzinom
Moll, I. (2019) · Der Pathologe · doi:10.1007/s00292-019-00705-7 · Cited by 8
Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage
Fukuda, R., Sugawara, S., & Kondo, Y. (2020) · Internal Medicine · doi:10.2169/internalmedicine.3726-19 · Cited by 9
Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma
Feng, Y., Song, X., & Jia, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.625360 · Cited by 8
Talimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma
Cilento, M. A., Klein, O., Egan, E., & Roberts‐Thomson, R. (2022) · Australasian Journal of Dermatology · doi:10.1111/ajd.13881 · Cited by 8
Primary pulmonary lymphoepithelioma‐like carcinoma treated with immunotherapy: A case report and literature review
Archwamety, A., Ruangchira‐urai, R., Akewanlop, C., & Korphaisarn, K. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14580 · Cited by 8
Merkelzellkarzinom: kutane Manifestation einer hochmalignen Prä-/pro-B-Zell-Neoplasie?
Sauer, C. M., Chteinberg, E., Rennspiess, D., Kurz, A. K., & Hausen, A. Z. (2017) · Der Hautarzt · doi:10.1007/s00105-017-3945-0 · Cited by 8
Reprint of: Virus-Specific T Cells: Broadening Applicability
Barrett, A. J., Prockop, S. E., & Bollard, C. M. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.12.787 · Cited by 8
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience
Re, G. L., Re, F. L., Doretto, P., Conte, A. D., Amadio, M., Cozzi, C., Casarotto, M., Maruzzi, D., Marus, W., Ubiali, P., et al. (2018) · Cytokine · doi:10.1016/j.cyto.2018.06.005 · Cited by 8
Avancées thérapeutiques récentes dans la prise en charge du carcinome à cellules de Merkel
Tétu, P., Baroudjian, B., Madelaine, I., Delyon, J., & Lebbé, C. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.11.009 · Cited by 8
Usefulness of ulceration and hyperkeratosis as clinical predictors of Merkel cell polyomavirus‐negative and combined Merkel cell carcinoma: A retrospective study
Nagase, K., Kimura, H., Inoue, T. K., Shinogi, T., & NARISAWA, Y. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14743 · Cited by 8
Inmunoterapia en cáncer cutáneo no melanoma
Bassas, P., Aparicio, G., & Briones, V. G.-P. (2019) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2018.09.013 · Cited by 8
Combined radio-immunotherapy leads to complete clinical regression of stage IV Merkel cell carcinoma
Principe, D. R., Clark, J. I., Emami, B., & Borowicz, S. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-230518 · Cited by 8
Merkel cell carcinoma (MCC) – neuroendocrine skin cancer
Dudzisz‐Śledź, M., Zdzienicki, M., & Rutkowski, P. L. (2019) · Nowotwory Journal of Oncology · doi:10.5603/njo.2019.0022 · Cited by 8
Tumor infiltrating lymphocyte grade in Merkel cell carcinoma: relationships with clinical factors and independent prognostic value
Yusuf, M. B., Gaskins, J., Mandish, S. F., May, M. E., Wall, W. B., Fisher, W., Tennant, P., Jorgensen, J., Bumpous, J. M., & Dunlap, N. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1794033 · Cited by 8
Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report
Cuenca, A. G., Rosales, I. A., Lee, R. J., Wu, C., Colvin, R. B., Feldman, A. S., Efstathiou, J. A., TOLKOFF-RUBIN, N. E., & Elias, N. (2020) · Transplantation Proceedings · doi:10.1016/j.transproceed.2020.06.012 · Cited by 8
Retrospective Multicenter Analysis of the Outcome of a Re-Induction with Immune Checkpoint Inhibitors in Advanced Merkel Cell Carcinoma
Stege, H. M., Bradfisch, F., Fleischer, M. I., Mohr, P., Ugurel, S., Terheyden, P. A. M., Thiem, A., Kiecker, F., Leiter, U., Becker, J. C., et al. (2020) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00488-6 · Cited by 8
Ovarian Endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents
Nonomura, Y., Nakayama, K., Nakamura, K., Razia, S., Yamashita, H., Ishibashi, T., Ishikawa, M., Sato, S., Nakayama, S., Otsuki, Y., et al. (2022) · Healthcare · doi:10.3390/healthcare10040694 · Cited by 8
Immune-based therapeutic approaches to virus-associated cancers
Smith, C., & Khanna, R. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.08.010 · Cited by 8
Heterogeneity of programmed death‐ligand expression in a case of Merkel cell carcinoma exhibiting complete regression after multiple metastases
Nakamura, M., Magara, T., Kobayashi, Y., Kato, H., Watanabe, S., & Morita, A. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17430 · Cited by 8
Pembrolizumab as first line treatment of Merkel cell carcinoma patients – a case series of patients with various co-morbidities
Boyles, T. B., Schødt, M., Hendel, H. W., Krarup‐Hansen, A., & Junker, N. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1747637 · Cited by 8
Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience
Hasmat, S., Howle, J. R., Karikios, D. J., Carlino, M. S., & Veness, M. (2021) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13243 · Cited by 8
Management and Future Therapeutic Perspectives of Classic Kaposi’s Sarcoma: An Evidence-Based Review
Denaro, N., Indini, A., Brambilla, L., Marzano, A. V., Garrone, O., & Tourlaki, A. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s468787 · Cited by 7
Merkel Cell Carcinoma: Current Treatment Landscape and Emerging Therapeutic Targets
Pan, K., Vromans, A. M., Liang Cheng, C., Grant-Kels, J. M., Katz, S. C., & Hadfield, M. J. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01693-z · Cited by 7
Real-world outcomes of patients receiving salvage therapies for immune checkpoint inhibitor-resistant Merkel cell carcinoma: a rationale for future clinical trials
Ch’en, P. Y., Zhang, Y., Hippe, D. S., Akaike, T., Miller, N. J., Church, C. D., Lachance, K., Finberg, A., Gooley, T. A., Hall, E. T., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012660 · Cited by 7
Self-citation
Immune PET Imaging
Iyalomhe, O., & Farwell, M. D. (2021) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2021.05.010 · Cited by 7
Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
Alloghbi, A., Ninia, J. G., Al-Share, B. A., Hotaling, J. M., Raza, S., & Sukari, A. W. (2021) · Clinical Case Reports · doi:10.1002/ccr3.5228 · Cited by 7
Single-Molecule RNA Sequencing Reveals IFNγ-Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus–Positive MCC Cell Lines
Sauerer, T., Lischer, C., Weich, A., Berking, C., Vera, J., & Dörrie, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.785662 · Cited by 7
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy
Bigelow, E., Saria, S., Piening, B., Curti, B. D., Dowdell, A. K., Weerasinghe, R. K., Bifulco, C. B., Urba, W. J., Finkelstein, N., Fertig, E. J., et al. (2022) · Cancer Informatics · doi:10.1177/11769351221136081 · Cited by 7

Authors: Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., Friedlander, P. A., Kluger, H. M., Kohrt, H. E., Lundgren, L., Margolin, K., Mitchell, A., Olencki, T., Pardoll, D. M., Reddy, S. A., Shantha, E. M., Sharfman, W. H., Sharon, E., Shemanski, L. R., Shinohara, M. M., Sunshine, J. C., Taube, J. M., Thompson, J. A., Townson, S. M., Yearley, J. H., Topalian, S. L., & Cheever, M. A.
Affiliations: Johns Hopkins University (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Mount Sinai Hospital (US)
ORCID: Nghiem, Paul T.
Bhatia, Shailender
Lipson, Evan J.
Kudchadkar, Ragini R.
Miller, Natalie J.
Berry, Sneha
Chartash, Elliot K.
Daud, Adil
Fling, Steven P.
Friedlander, Philip A.
Kluger, Harriet M.
Lundgren, Lisa
Margolin, Kim
Pardoll, Drew M.
Reddy, Sunil A.
Sharfman, William H.
Sharon, Elad
Shinohara, Michi M.
Sunshine, Joel C.
Taube, Janis M.
Thompson, John A.
Topalian, Suzanne L.
Cheever, Martin A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2016-06-30
Volume: 374
Issue: 26
Pages: 2542-2552
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1603702
PMC: PMC4927341
OpenAlex: W2339890238
Cited by: 1,258
References: 42
Citations by year: 2026: 40 · 2025: 68 · 2024: 76 · 2023: 86 · 2022: 104 · 2021: 141 · 2020: 166 · 2019: 172 · 2018: 187 · 2017: 174 · 2016: 40
FWCI: 103.02
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: National Institutes of Health (5u01ca154967-06)
National Cancer Institute (U01-CA-154967, R01CA162522, 1U01CA154967, K24CA139052, UM1CA154967, R01CA142779, P30CA006973)
National Institute of General Medical Sciences (T32GM007266)
Topics: Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
Keywords: Merkel cell carcinoma, pembrolizumab, anti-PD-1 therapy, immune checkpoint inhibitors, Merkel cell polyomavirus, PD-L1 expression, first-line therapy, objective response rate, progression-free survival, cutaneous squamous cell carcinoma, immune-related adverse events, treatment-related adverse events, treatment duration, drug safety and efficacy
MeSH terms: Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Neoplasm Staging, Recurrence, Skin Neoplasms, Carcinoma, Merkel Cell, Disease-Free Survival, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks